Citicoline, CDP-Choline Cancer Research Results

Citicoline, Citicoline, CDP-Choline: Click to Expand ⟱
Features:

Citicoline (CDP-Choline; Cytidine 5′-Diphosphocholine) — Endogenous intermediate in the Kennedy pathway of phosphatidylcholine synthesis and a neuroactive compound used as a dietary supplement and therapeutic agent in several countries. After oral administration, citicoline is hydrolyzed to choline and cytidine/uridine, which cross the blood-brain barrier and are reutilized for phospholipid and neurotransmitter synthesis.

Primary neurologic relevance: Citicoline has been studied extensively in ischemic stroke, traumatic brain injury, cognitive impairment, glaucoma, and neurodegenerative disorders. Reported actions include stabilization of neuronal membranes, phosphatidylcholine synthesis ↑, acetylcholine synthesis ↑, mitochondrial function support, oxidative stress ↓, excitotoxicity ↓, and neuronal repair signaling ↑.

Stroke relevance: Strong biologic rationale and substantial clinical research, although large randomized trials have produced mixed results for major functional outcomes in acute ischemic stroke. Citicoline remains widely studied and used as a neuroprotective and recovery-support compound.

Alzheimer’s disease / cognition relevance: Moderate evidence. Citicoline may improve selected cognitive outcomes, particularly attention, memory, and executive function in some populations, but evidence is insufficient to classify it as a disease-modifying Alzheimer’s treatment.

Cancer relevance: Limited. Citicoline is not generally considered an anticancer agent and should primarily be categorized for neurologic and metabolic effects.

Typical mechanisms: Phosphatidylcholine synthesis ↑; neuronal membrane repair ↑; acetylcholine synthesis ↑; dopamine signaling modulation; oxidative stress ↓; excitotoxicity ↓; mitochondrial function support; apoptosis ↓ in injured neural tissue.

Typical oral dose: Common supplemental and clinical-study doses are approximately 500–2000 mg/day, often divided once or twice daily depending on indication.

Recommended abbreviation: Citicoline or CDP-Choline.

product classification: Neuroprotective compound / phospholipid precursor / nootropic.

Citicoline (CDP-Choline; Cytidine 5′-Diphosphocholine) — An endogenous nucleotide intermediate in the Kennedy pathway of phosphatidylcholine synthesis and an orally available choline/cytidine precursor used as a neuroprotective and cognitive-support compound. It is formally classified as a phospholipid precursor, neuroprotective agent, nootropic/nutraceutical, and in some countries a therapeutic drug. Standard abbreviations include CDP-Choline and CDP-choline. Exogenous citicoline is generally produced by chemical or biotechnological synthesis rather than extracted from food. After oral administration it is extensively hydrolyzed; in humans, circulating choline and uridine appear to be the principal substrates contributing to subsequent brain phospholipid synthesis. Citicoline is licensed in Canadian natural health products and is authorized in the European Union as a novel food ingredient under specified conditions of use.

Primary mechanisms (ranked):

  1. Phosphatidylcholine and neuronal membrane phospholipid synthesis ↑, supporting membrane maintenance and repair.
  2. Membrane phospholipid degradation ↓, including attenuation of injury-associated phospholipase A2 activation and preservation of phosphatidylcholine, sphingomyelin and mitochondrial cardiolipin.
  3. Cholinergic neurotransmission support through provision of choline substrate and acetylcholine synthesis ↑.
  4. Dopaminergic and other monoaminergic neurotransmission modulation, with experimental evidence for dopamine and norepinephrine ↑.
  5. Mitochondrial membrane integrity and cellular energy function ↑, particularly under ischemic, oxidative or other neuronal stress.
  6. Oxidative stress and lipid peroxidation ↓ through preservation of membrane lipids and enhancement of glutathione-dependent antioxidant capacity.
  7. Excitotoxic neuronal injury ↓ and glutamate homeostasis support in experimental ischemic and excitotoxic models.
  8. Apoptosis ↓ in injured neurons through stabilization of mitochondrial function and modulation of pro- and anti-apoptotic signaling.

Bioavailability / PK relevance: Oral absorption of radiolabeled citicoline-derived material is nearly complete, but intact citicoline undergoes extensive intestinal and hepatic metabolism. Human studies show dose-dependent plasma choline increases and substantial plasma uridine increases after oral dosing; plasma cytidine is generally very low or undetectable. A 500 mg oral dose can elevate circulating choline for approximately 5 hours and uridine for approximately 5–6 hours, while higher doses prolong choline exposure. Thus, brain effects should be interpreted primarily as precursor-driven metabolic effects rather than direct sustained exposure of the CNS to intact citicoline.

In-vitro vs systemic exposure relevance: Concentration matching is important. Experimental studies sometimes expose cells directly to approximately 0.1–1 mM citicoline, whereas orally administered citicoline is substantially hydrolyzed before systemic distribution. Direct millimolar citicoline exposure therefore should not automatically be considered representative of human oral supplementation; mechanistic findings at high direct concentrations require pharmacokinetic qualification.

Clinical evidence status: RCT evidence exists, but efficacy is indication-dependent. Acute ischemic stroke has extensive clinical study, including a large negative phase III trial; citicoline should not be considered an established acute-stroke efficacy treatment based on current high-quality evidence. A large phase III traumatic brain injury trial was also negative. Smaller randomized studies suggest possible improvement in selected memory outcomes in older adults, while evidence in Alzheimer’s disease and established dementia remains limited and insufficient for disease-modifying claims. Glaucoma has supportive but still evolving adjunctive clinical evidence. Safety is generally favorable at commonly studied oral doses of approximately 500–2000 mg/day, although regulatory permitted supplemental doses vary by jurisdiction.

Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Phosphatidylcholine and membrane synthesis ↔ / not established ↑ Membrane synthesis and repair ↑ Central biochemical role of citicoline. Strongest relevance is neuronal and other normal-cell membrane homeostasis rather than cancer therapy.
2 Phospholipase A2 and membrane degradation Not established ↓ Phospholipid degradation ↓ Experimental ischemia studies show attenuation of injury-associated PLA2 activation; citicoline is not considered a direct PLA2 inhibitor.
3 Mitochondrial membrane integrity Not established ↑ Mitochondrial preservation ↑ Preservation of cardiolipin and mitochondrial homeostasis contributes to cytoprotection in stressed neural tissue.
4 Acetylcholine synthesis Not established ↑ Cholinergic neurotransmission ↑ Choline released from citicoline provides substrate for acetylcholine synthesis; most relevant to CNS function.
5 Dopaminergic signaling Not established ↑ / modulation Dopaminergic neurotransmission support Primarily supported by experimental pharmacology; clinical relevance varies with neurologic indication.
6 Oxidative stress and lipid peroxidation Not established ↓ Oxidative membrane injury ↓ Includes lipid peroxidation ↓ and preservation or restoration of antioxidant capacity under cellular stress.
7 Glutathione antioxidant system Not established ↑ GSH-dependent antioxidant defense ↑ Experimental studies report glutathione synthesis and glutathione reductase activity ↑.
8 Glutamate excitotoxicity Not established ↓ Excitotoxic neuronal injury ↓ Supported predominantly by preclinical ischemia and neuronal injury models.
9 Mitochondrial apoptosis Not established ↓ Stress-induced apoptosis ↓ Experimental neuronal models show Bax and caspase-3 signaling ↓ and Bcl-2 ↑. This cytoprotective profile does not support classification as an anticancer agent.
10 Na+/K+-ATPase function Not established ↑ / restoration Membrane ion-homeostasis support Reported primarily in experimental cerebral injury models.
11 Clinical Translation Constraint No established anticancer efficacy Context-dependent Translation limited by indication and PK Oral citicoline is extensively hydrolyzed; direct high-concentration cellular exposure is not equivalent to human oral exposure. Large RCTs were negative for acute ischemic stroke and traumatic brain injury despite substantial preclinical neuroprotection.





Alzheimer’s disease relevance: Citicoline has mechanistic relevance to Alzheimer’s disease through phosphatidylcholine synthesis, membrane maintenance, cholinergic substrate provision, mitochondrial protection, oxidative-stress reduction and anti-apoptotic effects. Experimental beta-amyloid plus cerebral-hypoperfusion models show reduced hippocampal neuronal degeneration and apoptosis. A small randomized placebo-controlled trial in mild-to-moderate Alzheimer’s disease reported selected cognitive and cerebral-perfusion effects, particularly in some subgroups, but the study was small and subsequent evidence has not established citicoline as a disease-modifying Alzheimer’s treatment. Current evidence is better characterized as neuroprotective/cognitive-supportive rather than anti-amyloid or disease modifying.

Clinical evidence status: Small human studies / limited RCT evidence. Potential adjunctive cognitive support, but insufficient evidence for treatment or prevention of Alzheimer’s disease. Evidence for age-associated memory impairment is somewhat stronger than evidence specifically for diagnosed Alzheimer’s disease.

Alzheimer’s Disease Mechanisms

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Phosphatidylcholine and neuronal membrane homeostasis ↑ Membrane synthesis and turnover support Central biochemical rationale; age and neurodegeneration are associated with altered neuronal membrane phospholipid metabolism.
2 Cholinergic neurotransmission ↑ Acetylcholine substrate availability ↑ Choline generated from oral citicoline can contribute to acetylcholine synthesis, providing a mechanistic rationale for cognitive effects.
3 Mitochondrial membrane integrity ↑ Mitochondrial resilience ↑ Includes preservation of cardiolipin and mitigation of stress-induced mitochondrial dysfunction.
4 Oxidative stress and lipid peroxidation ↓ Oxidative neuronal injury ↓ Supported predominantly by preclinical neuronal and ischemic models.
5 Glutathione antioxidant defense ↑ Cellular antioxidant capacity ↑ Citicoline has been associated experimentally with GSH synthesis and glutathione reductase activity ↑.
6 Beta-amyloid-associated neuronal apoptosis ↓ Neuronal apoptosis ↓ Demonstrated in an experimental beta-amyloid plus cerebral-hypoperfusion rat model; does not establish direct amyloid clearance or reduced amyloid production in humans.
7 Excitotoxicity ↓ Glutamate-mediated neuronal damage ↓ Mechanistically plausible and supported by injury models, but direct AD clinical evidence is limited.
8 Dopaminergic signaling ↑ / modulation Neurotransmitter signaling support Secondary mechanism relative to phospholipid and cholinergic effects in the AD context.
9 Clinical Translation Constraint Context-dependent Clinical benefit uncertain Small AD studies and preclinical results have not been confirmed by sufficiently large modern Alzheimer’s RCTs; no established disease-modifying activity.


Scientific Papers found: Click to Expand⟱
6117- Chol,  Citicoline,    Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Trial, AD, NA
*memory↑, *TMAO∅, *Dose↝,
8990- Citicoline,    Effect of oral CDP-choline on plasma choline and uridine levels in humans
- Trial, Nor, NA
*Dose?, *Uridine↑, *other↑,
8991- Citicoline,    Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study
- Human, Nor, NA
*PDE↑, *Dose?, *Learn↑,
8992- Citicoline,    Citicoline: neuroprotective mechanisms in cerebral ischemia
- Review, Stroke, NA
*Stroke↓, *other↝, *other↝, *other?, *GSH↑, *GPx↑, *lipid-P↓, *ATPase↑, *Ach↑,
8993- Citicoline,    Citicoline protects against lead-induced oxidative injury in neuronal PC12 cells
- in-vitro, Nor, PC12
*Apoptosis↓, *lipid-P↓, *TAC↑, *Catalase↑, *SOD↑, *GSH↑, *BAX↓, *Bcl-2↑, *Casp3↓, *neuroP↑, *ROS↓,
8994- Citicoline,    Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion
- Trial, AD, NA
*Dose?, *cognitive↑, *BloodF↑, *other↝, *IL1β↓, *eff↑,
8995- Citicoline,    Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport
- in-vivo, Stroke, NA
*Dose↝, *Stroke↓, *other↝, *ATP↑, *neuroP↑,
8996- Citicoline,    Effect of citicoline on cognitive function and functional recovery in patients with mild-to-moderate traumatic brain injury: a randomized placebo-controlled trial
- Trial, Nor, NA
*Dose?, *cognitive↑,
8997- Citicoline,    The Real-World Early Neuroprotective Effects of Oral Citicoline Combination in Prodromal Dementia
- Trial, AD, NA
*cognitive↑, *motorD↑, *memory↑, *Mood↑, *antiD↑, *ANXi↓,
8998- Citicoline,  Rad,    The impact of citicoline on brain mitochondrial dysfunction induced in rats after head irradiation
- in-vivo, Nor, NA
*Dose↝, *ROS↓, *compI↑, *compIII↑, *ATP↑, *Ca+2↓, *Iron↓, *Casp3↓, *glucose↝, *ACE/ACE1↑, *AChE↓,
8999- Citicoline,    Citicoline for Supporting Memory in Aging Humans
- Review, AD, NA
*memfluid↑,
9000- Citicoline,    The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives
- Review, AD, NA
*BioAv↑, *cognitive↑, *SIRT1↑, *eff↑, *neuroP↑,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   GPx↑, 1,   GSH↑, 2,   Iron↓, 1,   lipid-P↓, 2,   ROS↓, 2,   SOD↑, 1,   TAC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↑, 1,   compIII↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ATP↑, 2,   glucose↝, 1,   PDE↑, 1,   SIRT1↑, 1,   Uridine↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

other?, 1,   other↑, 1,   other↝, 4,  

Migration(tgid=13) ⓘ

ATPase↑, 1,   Ca+2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

memfluid↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

Ach↑, 1,   AChE↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACE/ACE1↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Dose?, 4,   Dose↝, 3,   eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF↑, 1,   TMAO∅, 1,  

Functional Outcomes(tgid=23) ⓘ

antiD↑, 1,   ANXi↓, 1,   cognitive↑, 4,   Learn↑, 1,   memory↑, 2,   Mood↑, 1,   motorD↑, 1,   neuroP↑, 3,   Stroke↓, 2,  
Total Targets: 44

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:500  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page